CtBP was first identified as a binding partner of the adenovirus oncoprotein E1A [79]–[80] and promotes cell survival, invasion and metastatic potential through transcriptional repression of a diverse range of tumour suppressors including E-cadherin, PTEN and p16INK4a (reviewed in [67]). The gene discussed is CDKN2A; the disease is neoplasm.